Polyrizon Ltd. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841). Its latest filed balance sheet (2025-12-31) shows total assets of $21 million (its filed statements).
Product businessSurgical & Medical Instruments & Apparatusfilings since 20222 of 9 filed, 7 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.2 out of ten, 2 of 9 metrics filed and 7 estimated: past 7.0 out of ten, present 6.8 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2022. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 105 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 8.9 out of ten. CrossAssetData estimate 8.9/10, confidence 35 of 100 (one part). 89th percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 8.7 out of ten. ROE -16%: lost 16¢ per shareholder dollar. Leverage 2%: owes 2¢ per asset dollar. 87th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 109 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 105 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 4.2 out of ten. CrossAssetData estimate 4.2/10, confidence 35 of 100 (one part). 42nd percentile among 120 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 20 of 100 (family median). 50th percentile among 105 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 88 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-03-25 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form S-8, 2026-10-07. Filings on record since 2022. Read from EDGAR 2026-10-12.
Who runs it
Izraeli, Tomer (Chief Executive Officer); Benyosef, Nir (Chief Financial Officer); Turgeman, Tidhar (Chief Technology Officer); Ron, Eyal S (Chief Science Officer); Adler, Oz (director); Carmel, Liron (director); Itzhaik, Asaf (director); Sidi, Liat (director); Vinokur, Yehonatan Zalman (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.